Lion Biotechnologies’ (LBIO) “Buy” Rating Reaffirmed at Roth Capital
Roth Capital restated their buy rating on shares of Lion Biotechnologies Inc. (NASDAQ:LBIO) in a research note released on Monday morning. The firm currently has a $15.00 price objective on the biotechnology company’s stock.
Other equities research analysts also recently issued reports about the company. Chardan Capital set a $20.00 target price on Lion Biotechnologies and gave the company a buy rating in a report on Sunday, August 21st. Jefferies Group reiterated a buy rating and set a $13.00 target price on shares of Lion Biotechnologies in a report on Monday, November 7th. Cowen and Company reiterated a buy rating on shares of Lion Biotechnologies in a report on Friday, November 4th. Finally, Zacks Investment Research upgraded Lion Biotechnologies from a sell rating to a hold rating in a report on Wednesday, October 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $18.29.
Shares of Lion Biotechnologies (NASDAQ:LBIO) opened at 6.95 on Monday. Lion Biotechnologies has a 1-year low of $4.24 and a 1-year high of $9.58. The stock’s 50 day moving average price is $6.74 and its 200 day moving average price is $7.62. The stock’s market cap is $431.50 million.
ILLEGAL ACTIVITY NOTICE: “Lion Biotechnologies’ (LBIO) “Buy” Rating Reaffirmed at Roth Capital” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/29/lion-biotechnologies-lbio-buy-rating-reaffirmed-at-roth-capital.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LBIO. KCG Holdings Inc. bought a new position in Lion Biotechnologies during the third quarter worth about $101,000. Stevens Capital Management LP bought a new position in Lion Biotechnologies during the third quarter worth about $118,000. Quantitative Investment Management LLC bought a new position in Lion Biotechnologies during the second quarter worth about $117,000. TD Asset Management Inc. bought a new position in Lion Biotechnologies during the third quarter worth about $123,000. Finally, Geduld E E raised its position in Lion Biotechnologies by 50.0% in the third quarter. Geduld E E now owns 15,000 shares of the biotechnology company’s stock worth $123,000 after buying an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 79.62% of the company’s stock.
Lion Biotechnologies Company Profile
Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.
Receive News & Stock Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related stocks with our FREE daily email newsletter.